We Develop New Treatments for Cancer and Inflammatory Eye Diseases

We Develop New Treatments for Cancer and Inflammatory Eye Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in hematological cancers, non-infectious uveitis and in solid tumors for naptumomab in partnership with NeoTX.

  • Presentation at ASH 2025

    Preclinical data with tasquinimod in combination with T-cell activation shows enhanced anti-tumor efficacy

    Read More See the poster

  • Presentation at FLORetina 2025

    Laquinimod and the LION study results will be presented at two oral sessions during the prestigious international 2025 FLORetina meeting held in Florence, Italy on December 4-7

    Read More

About Active Biotech

Tasquinimod
Laquinimod
Naptumomab

Projects

Stora Aktiedagarna Stockholm

Pipeline

Fully owned projects

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Hematological malignancies
Tasquinimod Multiple myeloma*
Tasquinimod Myelofibrosis
Tasquinimod Myelofibrosis
Inflammatory eye disorders
Laquinimod eye drops, safety and tolerability
Laquinimod eye drops, ocular biodistribution
Study ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Licensed projects

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Press Releases

Financial Reports

Latest Presentation

Redeye: Active Biotech (Intervju): Redeye pratar med vd Helén Tuvesson om nuläget (in Swedish)

Events and Financial Calendar

Year-end Report 2025
Date: February 12, 2026
Interim Report Jan-Mar 2026
Date: May 7, 2026
Annual General Meeting 2026
Date: May 20, 2026